Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Consequences of involuntary dose reductions during shortage of agalsidase beta - lessons learned from patients suffering from Fabry disease

  • In: A8 - Clinical consequences of medicine shortages on Wednesday, 3 September 2014, 14:00-17:00
  • At: Bangkok (Thailand) (2014)
  • Type: Presentation
  • By: LINTHORST, Gabor (Academic Medical Center, Endocrinology and metabolism, Amsterdam, Netherlands)
  • Co-author(s): Smid, Bouwien (Academic Medical Center, Amsterdam, Netherlands)
    Hollak, Carla (Academic Medical Center, Amsterdam, Netherlands)
  • Abstract:

    Background: Treatment with biweekly infusions with alpha-Galactosidase A (aGal A) is the only specific treatment for Fabry disease (aGal A deficiency), using either agalsidase alfa 0,2mg/kg/2wks or agalsidase beta 1,0 mg/kg/2wks (authorized in the EU)). In 2009 due to a viral contamination in the agalsidase beta production facility, a worldwide

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses